USRE40862E1 - Gossypolone for the treatment of cancer - Google Patents
Gossypolone for the treatment of cancer Download PDFInfo
- Publication number
- USRE40862E1 USRE40862E1 US11/581,734 US58173406A USRE40862E US RE40862 E1 USRE40862 E1 US RE40862E1 US 58173406 A US58173406 A US 58173406A US RE40862 E USRE40862 E US RE40862E
- Authority
- US
- United States
- Prior art keywords
- cancer
- gossypol
- gossypolone
- human
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 64
- 201000011510 cancer Diseases 0.000 title claims abstract description 27
- YSPBCFMMSKAENM-UHFFFAOYSA-N 7-(8-formyl-6,7-dihydroxy-3-methyl-1,4-dioxo-5-propan-2-ylnaphthalen-2-yl)-2,3-dihydroxy-6-methyl-5,8-dioxo-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound OC1=C(O)C(C=O)=C2C(=O)C(C=3C(=O)C=4C(C=O)=C(O)C(O)=C(C=4C(=O)C=3C)C(C)C)=C(C)C(=O)C2=C1C(C)C YSPBCFMMSKAENM-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 238000011282 treatment Methods 0.000 title claims description 31
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims abstract description 158
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims abstract description 78
- 229930000755 gossypol Natural products 0.000 claims abstract description 78
- 229950005277 gossypol Drugs 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 30
- 241000282414 Homo sapiens Species 0.000 claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 230000001093 anti-cancer Effects 0.000 claims abstract description 12
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 11
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 230000002611 ovarian Effects 0.000 claims description 7
- 230000001817 pituitary effect Effects 0.000 claims description 7
- 230000002381 testicular Effects 0.000 claims description 7
- 210000001685 thyroid gland Anatomy 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 230000001919 adrenal effect Effects 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 201000002511 pituitary cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- LJKDPUCDUDLUOM-UHFFFAOYSA-N [3,8-diacetyloxy-1-formyl-6-methyl-4-propan-2-yl-7-(1,6,7-triacetyloxy-8-formyl-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalen-2-yl] acetate Chemical compound CC(C)C1=C(OC(C)=O)C(OC(C)=O)=C(C=O)C2=C(OC(C)=O)C(C=3C(OC(C)=O)=C4C(C=O)=C(OC(C)=O)C(OC(C)=O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 LJKDPUCDUDLUOM-UHFFFAOYSA-N 0.000 abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 5
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 8
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 8
- 206010028813 Nausea Diseases 0.000 description 7
- 206010013781 dry mouth Diseases 0.000 description 7
- 230000008693 nausea Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 208000005946 Xerostomia Diseases 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000036765 blood level Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229960000350 mitotane Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
- 229960005314 suramin Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000013076 thyroid tumor Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 1
- LWOTXBQKJLOAOZ-UHFFFAOYSA-N 1-(6-methoxynaphthalen-2-yl)propan-1-one Chemical compound C1=C(OC)C=CC2=CC(C(=O)CC)=CC=C21 LWOTXBQKJLOAOZ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010049235 Nocturnal dyspnoea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
Definitions
- the present invention is related to the use of gossypol and related compounds as anti-tumor agents effective against human cancers including, but not limited to, adrenocortical carcinoma, uterine, cervical, ovarian and testicular carcinoma, breast cancer, and carcinoid tumors.
- Gossypol is a double biphenolic compound derived from crude cottonseed oil which has been shown to inhibit spermatogenesis, and which has been used extensively as a male contraceptive in China.
- gossypol While gossypol has been shown to retard the growth of some cancers in nude mice, its effects vary widely from species to species (Qian, S Z (1984) Ann. Rev. Pharmacol. Toxicol. 24: 329-60; Kim et al. (1984) Contraception 312: 5966-72).
- the effect of gossypol on the mitochondrial accumulation of rhodamine has been shown to be lower in magnitude in human cells than in rat testicular tumor cells (Tanphaichitr et al. (1984) Biol. of Reprod. 31: 1049-1060).
- mitotane ortho-para′-DDD
- a biphenolic compound which has been used to treat adrenal cancer
- the side effects produced at the doses required for response can be debilitating, and include anorexia, nausea, vomiting, and dizziness.
- Conventional chemotherapy such as with cytoxan, adriamycin, 5FU, and other agents has a low response rate, and side effects such as hair loss, bone marrow suppression, nausea, vomiting, and heart failure.
- an alternate or adjuvant therapy with less toxic side effects is desirable.
- gossypol and related compounds as anti-tumor agents against cancers in humans has yet to be reported.
- the present invention relates to the use of compounds with the following formula: in the treatment of human cancer, including treatment of adrenal, ovarian, thyroid, testicular, pituitary, prostate, and breast tumors, as well as other types of tumors.
- compositions useful in the present method of treatment include the formulation of gossypol and gossypol acetic acid, which contain both the positive and negative enantamers of gossypol, and formulations containing only one enantamer, as well as any physiologically acceptable salts, for either enteral or parenteral use. Such compositions also include those containing gossypolone. These compounds may be used alone, in combination with one another, or in combination with other conventional chemotherapeutic pharmaceutical compositions. The invention also includes the use of any metabolic products generated from gossypol which have anti tumor activity.
- gossypol and the related compounds noted above to treat human cancers is associated with milder side effects. These include mild fatigue, muscle tremor, dry mouth, dry skin, and occasional nausea. These are well tolerated, and patients are able to continue their normal activities.
- conventional chemotherapeutic agents are associated with a high degree of drug resistance.
- anti-tumor gossypol therapy has been demonstrated to be effective in patients who exhibit resistance to conventional anti-tumor agents.
- gossypol As gossypol is taken up into a number of human endocrine tissues, including the adrenal gland, testis, ovary, uterus, thyroid and pituitary, it can be used in the treatment of cancers of these organs, and against carcinoid tumors which are tumors of neuroendocrine tissue which may be located in the lung, pancreas, or gastrointestinal tract.
- gossypol has been found to retard the growth of some cancers in nude mice. However, its effects vary widely from species to species. It could not be assumed, therefore, that the anti-cancer effects seen in animals would be seen in humans.
- a further unexpected feature associated with the use of gossypol to treat cancer in human subjects as opposed to that in animals is that in the latter, higher doses of gossypol (e.g., 0.8 or 1.6 mg/mouse) have been shown to be lethal (Rao et al. (1985) Cancer Chemother. Pharmacol. 15: 20-25), negating any potential benefit of the drug in slowing cancer growth and prolonging survival.
- the present inventors have shown that the anti-tumor effect of gossypol in humans occurs at doses which are approximately one tenth of those effective in animals, i.e., 1 mg/kg/d vs. 10 mg/kg/d. Toxicity in humans begins to occur at doses greater than 1-2 mg/kg/d. Therefore, the studies of gossypol in animals do not make the use of gossypol for the treatment of cancer in humans, at appropriate doses, obvious in the latter.
- Existing therapies for the treatment of human tumors are multiple, including 5-fluorouracil, adriamycin, cytoxan, cisplatin, etoposide, suramin, and ortho-para′DDD (mitotane). These agents have a partial response rate of less than 20% for adrenocortical carcinoma, and less than 50% for other cancers.
- the toxicity of these agents which is not exhibited by gossypol, includes myelosuppression, nausea, vomitting, anorexia, hair loss, cardiac failure and neurotoxicity.
- anti-tumor agents with less toxicity which have activity against these tumors, and others, which are resistant to existing agents.
- Gossypol is a human anti-tumor agent which causes fewer side effects than such existing treatments.
- Another object of the present invention is to provide a method for treating cancer in a human which comprises administering to the subject an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-cancer effective amount of 5-fluorouracil, adriamycin, cytoxan, cisplatin, etoposide, suramin, mitotane, or other conventional chemotherapeutic agent, or combinations of these compounds.
- a further object of the present invention is to provide a pharmaceutical composition comprising an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-caner effective amount of the compounds listed above, or combinations of these compounds.
- FIG. 1 shows the effects on proliferation of SW-13 cells of 0, 0.5, 5, and 50 uM gossypol during prolonged exposure.
- SW-13 cells were seeded (1 ⁇ 10 4 cells) into 25 cm 2 tissue culture flasks in Dulbecco's minimal Eagle's medium supplemented with fetal calf serum (10%), 100 ug/ml streptomycin, 100 units/ml penicillin, and 2 mM glutamine. Exposure to 5 and 50 uM gossypol inhibited cell proliferation.
- FIG. 2 shows the effect of gossypol on the cumulative surface area of SW-13 human adrenocortical carcinoma in nude mice.
- Gossypol and placebo were given one month after the injection of tumor cells.
- Gossypol (mg/kg/day): ⁇ , ⁇ ; ⁇ , 30.
- Dulbecco's minimal Eagle's medium, fetal calf serum, glutamine, penicillin, and streptomycin were purchased from Quality Biological, Inc. (Gaithersburg, Md.); Hanks' balanced salt solution and trypsin-EDTA were obtained from Gibco Laboratories (Grand Island, N.Y.). 1,6-Diphenylhexatriene and tetrahydrofuran were from Aldrich Chemical Co., Inc. (Milwaukee, Wis.). Gossypol and gossypol acetic acid were gifts from the National Research Institute for Family Planning (Beijing, China). The established line of small cell human adrenocortical carcinoma (SW-13) was purchased from the American Type Culture Collection (Rockville, Md.).
- Sw-13 cells were seeded in a 25-cm 2 tissue culture flask (Costar, Cambridge, Mass.) at densities of 1 ⁇ 10 4 cells/5 ml of Dulbecco's minimal Eagle's medium, supplemented with 10% fetal calf serum, 100 ug/ml streptomycin, 100 units/ml penicillin, and 2 mM glutamine.
- the cells were grown in a humidified, 37° C. incubator with a 5% CO 2 /95% air atmosphere.
- a gossypol stock solution in absolute ethanol was added to the culture medium to yield final concentrations of 0, 0.5, 5, and 50 uM gossypol with a 0.1% final ethanol concentration.
- Adherent cells were typsinized (0.1% trypsin, w/v) and counted using a hemocytometer. Cell viability was determined by trypan blue exclusion.
- Nude mice (Charles River, Springfield, N.Y.) weighing 20-35 g were caged in a temperature-controlled (26-28° C.), 12 h/12 h light/dark animal room. A microporous cage bonnet served as an effective protective barrier between the animal and the outside environment. In addition, the room was continuously purged with High Efficiency Particle Attenuator-filtered air. The cages, feeders, and water bottles were designed to make standard mouse chow and water readily available while minimizing the opportunity for the transfer of communicable pathogens.
- mice Forty-nine adult male nude mice weighing 20-24 g were divided into two groups of 24 for control and 25 for gossypol treatment.
- Gossypol acetic acid was suspended in 75% ethanol for 24 h, then evaporated in vacuum chamber with desiccant, and finally suspended in sterilized 0.25% carboxymethylcellulose carrier.
- the gossypol-treated group received 30 mg gossypol/kg body weight/day via an orogastric tube. Control mice were fed an equal volume of carrier. Body weights were measured weekly.
- 2 ⁇ 10 6 SW-13 cells were injected s.c. on the back of these mice, which continued to receive gossypol or carrier for 5 additional weeks. Tumor surface areas (length ⁇ width, cm 2 ) were measured daily. After 5 weeks, the animals were decapitated.
- Another experiment was designed wherein 48 adult male nude mice weighing 25-35 g were injected s.c. with 2 ⁇ 10 6 SW-13 cells. One month later, the animals were divided into two groups of 24. There were 7 nude mice without visible tumors in each group. The gossypol treated animals received 30 mg gossypol acetic acid/kg body weight/day whereas control animals were fed an equal volume of carrier. Body weigths and tumor sizes (lengths ⁇ width, cm 2 ) were measured weekly. During the 12th week of treatment, 5 control animals died. Since it appeared unlikely that the remaining control animals would survive for another week, they were then sacrificed. Autopsies were performed on all animals including those that died during the study period. Internal organs were examined for the presence of gross tumor.
- nude mice had been given s.c. injections of SW-13 adrenocortical carcinoma 1 month prior to initiation of the treatment with either gossypol or carrier.
- the mean tumor sizes of the control and the gossypol treated groups were shown as a function of duration of treatment in Table 2.
- the slight decline in the mean tumor size observed towards the end of the study period was due to the fact that the majority of the control mice that died during the study has large tumors.
- the total tumor burden of the two groups rose during the treatment period, the controls reaching a value twice that of the gossypol group at the 12th week (FIG. 2 ).
- the patient had nocturnal dyspnea requiring supplemental oxygen therapy, markedly decreased exercise tolerance, persistent abdominal pain, and pedal edema.
- Physical examination revealed a cushingoid man with a blood pressure of 150/90, bilateral tender gynecomastia, a liver span of 14 cm, abdominal distension and fluid wave, and bilateral pitting edema to the knee.
- the method of the present invention includes the administration of gossypol, gossypol acetic acid, or gossypolone, alone or in combination with one another and/or other conventional chemotherapeutic agents, and a pharmaceutically acceptable excipient, to a human subject.
- compositions containing compounds according to the present invention are administered in an effective amount to a human host for the treatment of a variety of human cancers including adrenal, ovarian, thyroid, testicular, pituitary, prostate, and breast cancer.
- certain pharmaceutical compositions, doses, routes of administration, and desired blood levels may be employed. These are summarized in the table below.
- the indicated dose and blood level are approximate, e.g., for oral administration of gossypol acetic acid(+)-compressed tablet, the does may be from about 40 to about 100 mg/d, and the desired blood level may be from about 400 to about 800 ng/dl.
- the drug When administered orally, the drug may be taken in divided doses, two to three times a day.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method for treating cancer in a human, which comprises administering to the human subject an anti-cancer effective amount of a compound selected from gossypol, gossypol acetic acid, gossypolone, metabolites thereof, or physiologically acceptable salts thereof. Also included is a method for treating cancer in a human which comprises administering to the human subject an anti-cancer effective amount of any of the compounds listed above in combination with an anti-cancer effective amount of other conventional chemotherapeutic agents. Finally, the invention also encompasses a pharmaceutical composition comprising an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-cancer effective amount of a conventional chemotherapeutic agent, or combinations of the latter.
Description
Notice: More than one reissue application has been filed for the reissue of U.S. Pat. No. 6,114,397. The reissue applications are U.S. patent application Ser. Nos. 11/581,734 (the present application), filed Oct. 16, 2007, and 10/806,088, filed Mar. 22, 2004. U.S. patent application Ser. No. 08/379,872, filed Jan. 27, 1995, issued as U.S. Pat. No. 6,114,397, which is a divisional of U.S. patent application Ser. No. 07/551,353, filed Jul. 12, 1990, issued as U.S. Pat. No. 5,385,936.
1. Field of the Invention
The present invention is related to the use of gossypol and related compounds as anti-tumor agents effective against human cancers including, but not limited to, adrenocortical carcinoma, uterine, cervical, ovarian and testicular carcinoma, breast cancer, and carcinoid tumors.
2. Description of the Related Art
Gossypol is a double biphenolic compound derived from crude cottonseed oil which has been shown to inhibit spermatogenesis, and which has been used extensively as a male contraceptive in China.
While gossypol has been shown to retard the growth of some cancers in nude mice, its effects vary widely from species to species (Qian, S Z (1984) Ann. Rev. Pharmacol. Toxicol. 24: 329-60; Kim et al. (1984) Contraception 312: 5966-72). The effect of gossypol on the mitochondrial accumulation of rhodamine has been shown to be lower in magnitude in human cells than in rat testicular tumor cells (Tanphaichitr et al. (1984) Biol. of Reprod. 31: 1049-1060). Furthermore, closely related compounds such as mitotane (ortho-para′-DDD), a biphenolic compound which has been used to treat adrenal cancer, are only of limited effectiveness in treating cancer in humans. In addition, the side effects produced at the doses required for response can be debilitating, and include anorexia, nausea, vomiting, and dizziness. Conventional chemotherapy such as with cytoxan, adriamycin, 5FU, and other agents has a low response rate, and side effects such as hair loss, bone marrow suppression, nausea, vomiting, and heart failure. Clearly, an alternate or adjuvant therapy with less toxic side effects is desirable.
The use of gossypol and related compounds as anti-tumor agents against cancers in humans has yet to be reported.
The present invention relates to the use of compounds with the following formula:
in the treatment of human cancer, including treatment of adrenal, ovarian, thyroid, testicular, pituitary, prostate, and breast tumors, as well as other types of tumors.
in the treatment of human cancer, including treatment of adrenal, ovarian, thyroid, testicular, pituitary, prostate, and breast tumors, as well as other types of tumors.
Pharmaceutical compositions useful in the present method of treatment include the formulation of gossypol and gossypol acetic acid, which contain both the positive and negative enantamers of gossypol, and formulations containing only one enantamer, as well as any physiologically acceptable salts, for either enteral or parenteral use. Such compositions also include those containing gossypolone. These compounds may be used alone, in combination with one another, or in combination with other conventional chemotherapeutic pharmaceutical compositions. The invention also includes the use of any metabolic products generated from gossypol which have anti tumor activity.
As compared to conventional therapies, the use of gossypol and the related compounds noted above to treat human cancers is associated with milder side effects. These include mild fatigue, muscle tremor, dry mouth, dry skin, and occasional nausea. These are well tolerated, and patients are able to continue their normal activities. In addition, conventional chemotherapeutic agents are associated with a high degree of drug resistance. As discussed below, anti-tumor gossypol therapy has been demonstrated to be effective in patients who exhibit resistance to conventional anti-tumor agents.
As gossypol is taken up into a number of human endocrine tissues, including the adrenal gland, testis, ovary, uterus, thyroid and pituitary, it can be used in the treatment of cancers of these organs, and against carcinoid tumors which are tumors of neuroendocrine tissue which may be located in the lung, pancreas, or gastrointestinal tract.
As previously noted, gossypol has been found to retard the growth of some cancers in nude mice. However, its effects vary widely from species to species. It could not be assumed, therefore, that the anti-cancer effects seen in animals would be seen in humans. A further unexpected feature associated with the use of gossypol to treat cancer in human subjects as opposed to that in animals is that in the latter, higher doses of gossypol (e.g., 0.8 or 1.6 mg/mouse) have been shown to be lethal (Rao et al. (1985) Cancer Chemother. Pharmacol. 15: 20-25), negating any potential benefit of the drug in slowing cancer growth and prolonging survival. The present inventors have shown that the anti-tumor effect of gossypol in humans occurs at doses which are approximately one tenth of those effective in animals, i.e., 1 mg/kg/d vs. 10 mg/kg/d. Toxicity in humans begins to occur at doses greater than 1-2 mg/kg/d. Therefore, the studies of gossypol in animals do not make the use of gossypol for the treatment of cancer in humans, at appropriate doses, obvious in the latter.
Existing therapies for the treatment of human tumors, including adrenal, ovarian, thyroid, testicular, pituitary, prostate, and breast tumors, are multiple, including 5-fluorouracil, adriamycin, cytoxan, cisplatin, etoposide, suramin, and ortho-para′DDD (mitotane). These agents have a partial response rate of less than 20% for adrenocortical carcinoma, and less than 50% for other cancers. The toxicity of these agents, which is not exhibited by gossypol, includes myelosuppression, nausea, vomitting, anorexia, hair loss, cardiac failure and neurotoxicity. Thus, there is a need for anti-tumor agents with less toxicity which have activity against these tumors, and others, which are resistant to existing agents.
Gossypol is a human anti-tumor agent which causes fewer side effects than such existing treatments.
Accordingly, it is an object of the present invention to provide a method for treating cancer in a human, which comprises administering to the subject an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone.
Another object of the present invention is to provide a method for treating cancer in a human which comprises administering to the subject an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-cancer effective amount of 5-fluorouracil, adriamycin, cytoxan, cisplatin, etoposide, suramin, mitotane, or other conventional chemotherapeutic agent, or combinations of these compounds.
A further object of the present invention is to provide a pharmaceutical composition comprising an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-caner effective amount of the compounds listed above, or combinations of these compounds.
Further scope of the applicability of the present invention will become apparent from the detailed description and drawings provided below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
The above and other objects, features, and advantages of the present invention will be better understood from the following descriptions taken in conjunction with the accompanying drawings, in which:
Dulbecco's minimal Eagle's medium, fetal calf serum, glutamine, penicillin, and streptomycin were purchased from Quality Biological, Inc. (Gaithersburg, Md.); Hanks' balanced salt solution and trypsin-EDTA were obtained from Gibco Laboratories (Grand Island, N.Y.). 1,6-Diphenylhexatriene and tetrahydrofuran were from Aldrich Chemical Co., Inc. (Milwaukee, Wis.). Gossypol and gossypol acetic acid were gifts from the National Research Institute for Family Planning (Beijing, China). The established line of small cell human adrenocortical carcinoma (SW-13) was purchased from the American Type Culture Collection (Rockville, Md.).
Cell Proliferation
Sw-13 cells were seeded in a 25-cm2 tissue culture flask (Costar, Cambridge, Mass.) at densities of 1×104 cells/5 ml of Dulbecco's minimal Eagle's medium, supplemented with 10% fetal calf serum, 100 ug/ml streptomycin, 100 units/ml penicillin, and 2 mM glutamine. The cells were grown in a humidified, 37° C. incubator with a 5% CO2/95% air atmosphere. A gossypol stock solution in absolute ethanol was added to the culture medium to yield final concentrations of 0, 0.5, 5, and 50 uM gossypol with a 0.1% final ethanol concentration. After 1, 2, 4, or 6 days of incubation, the culture medium containing a few floating cells was removed. Adherent cells were typsinized (0.1% trypsin, w/v) and counted using a hemocytometer. Cell viability was determined by trypan blue exclusion.
As shown in FIG. 1 , exposure of SW-13 cells to 5 and 50 uM gossypol inhibited cell proliferation.
Nude Mice
Nude mice (Charles River, Kingston, N.Y.) weighing 20-35 g were caged in a temperature-controlled (26-28° C.), 12 h/12 h light/dark animal room. A microporous cage bonnet served as an effective protective barrier between the animal and the outside environment. In addition, the room was continuously purged with High Efficiency Particle Attenuator-filtered air. The cages, feeders, and water bottles were designed to make standard mouse chow and water readily available while minimizing the opportunity for the transfer of communicable pathogens.
Transplantation of SW-13 Cells
Forty-nine adult male nude mice weighing 20-24 g were divided into two groups of 24 for control and 25 for gossypol treatment. Gossypol acetic acid was suspended in 75% ethanol for 24 h, then evaporated in vacuum chamber with desiccant, and finally suspended in sterilized 0.25% carboxymethylcellulose carrier. The gossypol-treated group received 30 mg gossypol/kg body weight/day via an orogastric tube. Control mice were fed an equal volume of carrier. Body weights were measured weekly. At the end of the first week of gossypol treatment, 2×106 SW-13 cells were injected s.c. on the back of these mice, which continued to receive gossypol or carrier for 5 additional weeks. Tumor surface areas (length×width, cm2) were measured daily. After 5 weeks, the animals were decapitated.
Another experiment was designed wherein 48 adult male nude mice weighing 25-35 g were injected s.c. with 2×106 SW-13 cells. One month later, the animals were divided into two groups of 24. There were 7 nude mice without visible tumors in each group. The gossypol treated animals received 30 mg gossypol acetic acid/kg body weight/day whereas control animals were fed an equal volume of carrier. Body weigths and tumor sizes (lengths×width, cm2) were measured weekly. During the 12th week of treatment, 5 control animals died. Since it appeared unlikely that the remaining control animals would survive for another week, they were then sacrificed. Autopsies were performed on all animals including those that died during the study period. Internal organs were examined for the presence of gross tumor.
Statistical Analysis
Data are expressed as the mean±SD unless otherwise indicated. Statistical comparisons were made using an unpaired Student's t test.
Effect of Gossypol on SW-13 Tumor Bearing Nude Mice
In this experiment, nude mice had been given s.c. injections of SW-13 adrenocortical carcinoma 1 month prior to initiation of the treatment with either gossypol or carrier.
During the subsequent 12 weeks of treatment, there were 10 deaths in the control group: 4 had apparent ascites, were jaundiced, and had large intraperitoneal tumors; 2 suffered from hind leg paralysis due to a tumor metastatic to the spinal column; 2 animals had small tumors, but both showed significant weight loss; 2 had demonstrated neither visible tumors nor an obvious cause of death. In contrast, only two deaths were observed in the gossypol-treated group, one of them having ascites while the other had no apparent tumor at autopsy. Each treated mouse in the group received a total dose of 81.9 mg gossypol during the 12-week period.
As in the previous study, 12 weeks of gossypol treatment had no significant effect on body weights. At the end of the study period, the body weights in both groups were 32.2±3.8 and 30.9±3.6 g for the control and gossypol-treated groups, respectively. After 12 weeks of treatment, the tumor prevalence had risen from 71 to 83% in the control group, while the gossypol-treated group exhibited a decrease in tumor prevalence from 71% to 54%. This was accompanied by the death of 41.6% of the controls and 8.3% of the gossypol-treated group (Table 1).
TABLE 1 |
Effect of gossypol on tumor prevalence and mortality in mice |
having preexisting tumors |
Control (%) | Gossypol (%) |
Prevalence | Total | Prevalence | Total | ||
Week | of tumor | deaths | of | deaths | |
0 | 71 | 0 | 72 | 0 |
1 | 75 | 0 | 63 | 0 |
2 | 83 | 0 | 50 | 0 |
3 | 83 | 0 | 54 | 0 |
4 | 83 | 0 | 50 | 0 |
5 | 83 | 0 | 58 | 0 |
6 | 83 | 0 | 58 | 0 |
7 | 83 | 8.3 | 58 | 0 |
8 | 83 | 8.3 | 58 | 0 |
9 | 83 | 12.5 | 54 | 0 |
10 | 83 | 16.7 | 54 | 0 |
11 | 83 | 20.8 | 54 | 0 |
12 | 83 | 41.6 | 54 | 8.3 |
The mean tumor sizes of the control and the gossypol treated groups were shown as a function of duration of treatment in Table 2. The slight decline in the mean tumor size observed towards the end of the study period was due to the fact that the majority of the control mice that died during the study has large tumors.
TABLE 2 |
Effect of gossypol on mean tumor size |
Mean tumor size (cm2) (mean ± SE) |
| Control | Gossypol | |
0 | 0.09 ± 0.02 | 0.08 ± 0.02 |
1 | 0.22 ± 0.05 | 0.07 ± 0.02 |
2 | 0.28 ± 0.06 | 0.12 ± 0.04a |
3 | 0.35 ± 0.07 | 0.15 ± 0.05a |
4 | 0.50 ± 0.11 | 0.20 ± 0.07a |
5 | 0.66 ± 0.17 | 0.28 ± 0.08a |
6 | 0.87 ± 0.22 | 0.32 ± 0.10a |
7 | 0.97 ± 0.25 (n = 23) | 0.38 ± 0.12a |
8 | 1.16 ± 0.33 (n = 22) | 0.45 ± 0.14a |
9 | 1.07 ± 0.34 (n = 20) | 0.50 ± 0.15a |
10 | 1.14 ± 0.36 (n = 20) | 0.59 ± 0.18a |
11 | 1.39 ± 0.41 (n = 19) | 0.68 ± 0.21a |
12 | 0.96 ± 0.21 (n = 15) | 0.81 ± 0.25 (n = 22) |
aP < 0.05, control compared to gossypol treated group; n = 24 unless otherwise indicated. |
The total tumor burden of the two groups rose during the treatment period, the controls reaching a value twice that of the gossypol group at the 12th week (FIG. 2).
Treatment of Human Metastatic Adrenal Cancer
Previous medical therapy for metastatic adrenocortical carcinoma has been largely unsuccessful. Based on the growth inhibitory effect of gossypol on SW-13 human adrenocortical tumors in vivo in nude mice, discussed above, the effect of oral gossypol treatment on metastatic adrenal cancer in a human patient was investigated.
A 36 year old man presented with a left sided adrenocortical carcinoma, 26×13 cm, invading the kidney and inferior vena cava. Surgical excision of all visible tumor was performed, and the patient was started on mitotane postoperatively. Pulmonary metastases were found six months later, which were resected. Six month following thoracotomy, multiple hepatic metastases were found. His tumor progressed despite treatment with Suramin and adriamycin/VP16.
At the time of gossypol treatment, the patient had nocturnal dyspnea requiring supplemental oxygen therapy, markedly decreased exercise tolerance, persistent abdominal pain, and pedal edema. Physical examination revealed a cushingoid man with a blood pressure of 150/90, bilateral tender gynecomastia, a liver span of 14 cm, abdominal distension and fluid wave, and bilateral pitting edema to the knee.
Gossypol acetic acid, 10 mg compressed tablet, was given orally at a dose of 20 mg/d which was increased by 10 mg/d every three days to a dose of 50 mg/d.
During gossypol treatment, the patient experienced fatigue, xerostomia, tremor, and trasnminitis. After three weeks of gossypol treatment, CT scans showed complete resolution of pulmonary metastases and greather than 50% decreased in the size of the hepatic metastases, and an improvement in abdominal pain, ascites, and pulmonary function.
A summary of the results obtained in this and other human subjects during a phase I clinical trail of oral gossypol for the treatment of metastatic adrenocortical carcinoma is presented in Table 3.
TABLE 3 |
Summary of Preliminary Results of |
Oral Gossypol for Adrenocortical Cancer |
Age/Sex | Site | Dose | Duration | Level | Side Effects | Response |
36/M* | Lung | 40-60 | 28 | 463 | Xerostomia | Partial |
Liver | mg/d | weeks | ng/dl | Fatigue | Response | |
(*Patient | Gyneco- | |||||
described | mastia | |||||
above) | Trans- | |||||
aminitis | ||||||
26/M | Lung | 70 | 3 | 1,025 | Xerostomia | Pro- |
Liver | weeks | Nausea | gression | |||
Trans- | ||||||
aminitis | ||||||
52/F | Abdo- | 40 | 6 | 444 | Xerostomia | Partial |
men | weeks | Fatigue | Response | |||
Nausea | ||||||
34/M | Abdo- | 40-50 | 12 | 291 | Xerostomia | Stabili- |
men | weeks | Fatigue | zation | |||
Liver | Nausea | |||||
27/M | Abdo- | 50 | 6 | 229 | Xerostomia | Pro- |
men | weeks | Fatigue | gression | |||
Pelvis | ||||||
Of these five patients, two exhibited partial tumor responses, one has stable disease, and two showed tumor progression.
Pharmaceutical Compositions and Modes of Administration of Gossypol and Related Compounds
The method of the present invention includes the administration of gossypol, gossypol acetic acid, or gossypolone, alone or in combination with one another and/or other conventional chemotherapeutic agents, and a pharmaceutically acceptable excipient, to a human subject.
In the methods according to the present invention pharmaceutical compositions containing compounds according to the present invention are administered in an effective amount to a human host for the treatment of a variety of human cancers including adrenal, ovarian, thyroid, testicular, pituitary, prostate, and breast cancer.
In administering gossypol and related compounds for the treatment of cancer by the methods of the present invention, certain pharmaceutical compositions, doses, routes of administration, and desired blood levels may be employed. These are summarized in the table below. In each case, the indicated dose and blood level are approximate, e.g., for oral administration of gossypol acetic acid(+)-compressed tablet, the does may be from about 40 to about 100 mg/d, and the desired blood level may be from about 400 to about 800 ng/dl.
TABLE 4 |
Pharmaceutical Formulations, Doses, Routes of |
Administration, and Effective Blood Levels of |
Gossypol and Related Compounds for the Treatment |
of Human Cancer. |
Formulation | Route | Dose | Blood Level |
Gossypol acetic acid | Oral | 40-100 | mg/d | 400-800 | ng/dl |
(+)-compressed tablet | |||||
Gossypol acetic acid | Rectal, | 40-140 | mg/d | 400-1000 | ng/dl |
(+)-suppositories | vaginal | ||||
Gossypol(+)-PVP and | Parent- | 1-2 | mg/kg/d | 400-1000 | ng/dl |
physiologic salts | eral | ||||
Gossypol acetic acid | Oral | 40-100 | mg/d | 400-800 | ng/dl |
(x)-compressed tablet | |||||
Gossypol acetic acid | Rectal, | 40-140 | mg/d | 400-1000 | ng/dl |
(x)-suppositories | vaginal | ||||
Gossypol(x)-PVP and | Parent- | 1-2 | mg/kg/d | 400-1000 | ng/dl |
physiologic salts | eral | ||||
Gossypol(−)-tablet | Oral | 20-100 | mg/d | 200-1000 | ng/dl |
Gossypol(−)- | Rectal | 40-140 | mg/d | 200-1000 | ng/dl |
suppositories | |||||
Gossypol(−)-PVP and | Parent- | 1-2 | mg/kg/d | 200-1000 | ng/dl |
physiologic salts | eral | ||||
Gossypolone tablet | Oral | 50-200 | mg/d | 400-1000 | ng/dl |
Gossypolone | Rectal, | 50-200 | mg/d | 400-1000 | ng/dl |
suppositories | vaginal | ||||
Gossypolone PVP and | Parent- | 1-5 | mg/kg/d | 400-1000 | ng/dl |
physiologic salts | eral | ||||
When administered orally, the drug may be taken in divided doses, two to three times a day.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
Claims (20)
1. A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a physiologically acceptable salt of gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:
administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol, a physiologically acceptable salt of gossypol, gossypolone, and a physiologically acceptable salt of gossypolone, and with a pharmaceutically acceptable carrier, wherein the cancer is selected from the group consisting of adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.
2. The method of claim 1 , wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.
3. The method of claim 2 1, wherein said cancer is adrenal cancer.
4. The method of claim 1 , wherein the blood concentration of said compound is 400 200-1000 ng/dl.
5. The method of claim 4 , wherein said compound is gossypoloneor a physiologically acceptable salt of gossypolone .
6. The method of claim 5 4, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.
7. The method of claim 5 4, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.
8. A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, or a combination thereof, which method comprises:
administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9. The method of claim 8 , wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate or breast cancer.
10. The method of claim 8 , wherein said cancer is adrenal cancer.
11. The method of claim 8 , wherein the blood concentration of said compound is 400-1000 ng/dl.
12. The method of claim 8 , wherein said compound is administrated parenterally at a dose of 1-2 mg/d.
13. The method of claim 8 , wherein said compound is administered orally at a dose of 20-100 mg/d.
14. The method of claim 8 , wherein said compound is administered rectally at a dose of 40-140 mg/d.
15. The method of claim 1 , wherein said cancer is ovarian cancer.
16. The method of claim 1 , wherein said cancer is thyroid cancer.
17. The method of claim 1 , wherein said cancer is testicular cancer.
18. The method of claim 1 , wherein said cancer is pituitary cancer.
19. The method of claim 1 , wherein said cancer is prostate cancer.
20. The method of claim 1 , wherein said cancer is breast cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/581,734 USRE40862E1 (en) | 1990-07-12 | 2006-10-16 | Gossypolone for the treatment of cancer |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/551,353 US5385936A (en) | 1990-07-12 | 1990-07-12 | Gossypol acetic acid for the treatment of cancer |
US08/379,872 US6114397A (en) | 1990-07-12 | 1995-01-27 | Gossypol for the treatment of cancer |
US80608804A | 2004-03-22 | 2004-03-22 | |
US11/581,734 USRE40862E1 (en) | 1990-07-12 | 2006-10-16 | Gossypolone for the treatment of cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/379,872 Reissue US6114397A (en) | 1990-07-12 | 1995-01-27 | Gossypol for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE40862E1 true USRE40862E1 (en) | 2009-07-21 |
Family
ID=24200924
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/551,353 Expired - Lifetime US5385936A (en) | 1990-07-12 | 1990-07-12 | Gossypol acetic acid for the treatment of cancer |
US08/379,872 Ceased US6114397A (en) | 1990-07-12 | 1995-01-27 | Gossypol for the treatment of cancer |
US11/581,734 Expired - Lifetime USRE40862E1 (en) | 1990-07-12 | 2006-10-16 | Gossypolone for the treatment of cancer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/551,353 Expired - Lifetime US5385936A (en) | 1990-07-12 | 1990-07-12 | Gossypol acetic acid for the treatment of cancer |
US08/379,872 Ceased US6114397A (en) | 1990-07-12 | 1995-01-27 | Gossypol for the treatment of cancer |
Country Status (1)
Country | Link |
---|---|
US (3) | US5385936A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090105319A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
US20110112112A1 (en) * | 2009-10-08 | 2011-05-12 | Sanford-Burnham Medical Research Institute | Apogossypolone derivatives as anticancer agents |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597830A (en) * | 1994-12-20 | 1997-01-28 | Warner-Lambert Company | Combination chemotherapy |
CA2417500C (en) * | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
AU2002230888A1 (en) * | 2000-12-15 | 2002-06-24 | Wackvom Limited | Methods and compositions to treat conditions associated with neovascularization |
AU2002305769B2 (en) * | 2001-05-30 | 2007-07-19 | Georgetown University | Small molecule antagonists of Bcl2 family proteins |
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7354928B2 (en) * | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
DE10232723A1 (en) * | 2002-07-16 | 2004-02-05 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Test system for the detection of inhibitors of inositol phosphate kinases and uses of these inhibitors for the prophylaxis or therapy of proliferative diseases |
FR2843751B1 (en) * | 2002-08-20 | 2004-09-24 | Centre Nat Rech Scient | GOSSYPOL DERIVATIVES, PROCESSES FOR OBTAINING SAME, AND USES THEREOF |
PL1653943T6 (en) * | 2003-06-25 | 2009-02-27 | The Burnham Inst La Jolla | Catechol derivatives for the treatment of cancer |
FR2864955B1 (en) * | 2004-01-08 | 2006-03-10 | Centre Nat Rech Scient | GOSSYPOL DERIVATIVES, METHOD FOR OBTAINING THEM AND USES THEREOF |
AU2005228998B2 (en) * | 2004-03-25 | 2008-11-06 | The Regents Of The University Of Michigan | Gossypol co-crystals and the use thereof |
WO2006010073A1 (en) * | 2004-07-08 | 2006-01-26 | Threshold Pharmaceuticals, Inc. | Prevention of cancer |
US8557812B2 (en) * | 2004-08-20 | 2013-10-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
MX2007002104A (en) * | 2004-08-20 | 2007-10-10 | Univ Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof. |
US8193238B2 (en) * | 2006-03-08 | 2012-06-05 | University Of Maryland, Baltimore | Inhibition of microtubule protrusion in cancer cells |
JP2010529023A (en) * | 2007-05-31 | 2010-08-26 | アセンタ セラピューティックス インコーポレイティッド | Gossypol's rhythmic dosing for the treatment of disease |
WO2009114658A2 (en) * | 2008-03-12 | 2009-09-17 | University Of Maryland, Baltimore | Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer |
US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
BRPI1008745A2 (en) | 2009-02-05 | 2019-09-17 | Tokai Pharmaceuticals Inc | cyp17 / antiandrogen steroid inhibitor prodrugs |
EP2968370A4 (en) | 2013-03-14 | 2016-09-21 | Univ Maryland | Androgen receptor down-regulating agents and uses thereof |
AU2014306698A1 (en) | 2013-08-12 | 2016-01-28 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
CN108697667A (en) * | 2016-02-18 | 2018-10-23 | 延世大学校产学协力团 | For treating cancer, contain pharmaceutical composition of the polyphenolic substance as active constituent |
WO2017142348A1 (en) | 2016-02-18 | 2017-08-24 | 연세대학교 산학협력단 | Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient |
CN110143858B (en) | 2018-02-12 | 2022-04-29 | 华南理工大学 | Polysubstituted benzene compound with bioactivity and preparation method and application thereof |
KR102428313B1 (en) | 2018-07-09 | 2022-08-03 | 연세대학교 산학협력단 | A pharmaceutical composition for the treatment of brain cancer comprising aldehyde inhibitor, and an anticancer agent |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297341A (en) | 1980-05-09 | 1981-10-27 | University Of Illinois Foundation | Spermicidal composition |
US4806568A (en) | 1985-09-12 | 1989-02-21 | Research Corporation | Gossypol derivatives |
JPH01132542A (en) | 1987-11-19 | 1989-05-25 | Toomen:Kk | Method for optically resolving gossypol racemic modification |
US5026726A (en) | 1989-12-11 | 1991-06-25 | The University Of New Mexico | Gossylic iminolactones and gossylic lactones and their anti-viral activities |
US5260327A (en) | 1985-10-02 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine |
US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
US6608107B2 (en) | 2000-12-15 | 2003-08-19 | Wackvom Limited | Methods and compositions to treat conditions associated with neovascularization |
-
1990
- 1990-07-12 US US07/551,353 patent/US5385936A/en not_active Expired - Lifetime
-
1995
- 1995-01-27 US US08/379,872 patent/US6114397A/en not_active Ceased
-
2006
- 2006-10-16 US US11/581,734 patent/USRE40862E1/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297341A (en) | 1980-05-09 | 1981-10-27 | University Of Illinois Foundation | Spermicidal composition |
US4806568A (en) | 1985-09-12 | 1989-02-21 | Research Corporation | Gossypol derivatives |
US5260327A (en) | 1985-10-02 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine |
JPH01132542A (en) | 1987-11-19 | 1989-05-25 | Toomen:Kk | Method for optically resolving gossypol racemic modification |
US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
US5026726A (en) | 1989-12-11 | 1991-06-25 | The University Of New Mexico | Gossylic iminolactones and gossylic lactones and their anti-viral activities |
US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
US6608107B2 (en) | 2000-12-15 | 2003-08-19 | Wackvom Limited | Methods and compositions to treat conditions associated with neovascularization |
Non-Patent Citations (78)
Title |
---|
Band et al., "Antiproliferative Effect of Gossypol and Its Optical Isomers on Human Reproductive Cancer Cell Lines," Gynecologic Oncology, 32, 273-277 (1989). |
Band et al., "Cytocidal Effects of Gossypol and Its Optical Isomers on Reproductive Cancer Cell Lines," Gynecologic Oncologists, 23 (2), 261 (1986). |
Benz et al., "Biochemical Correlates of the Antitumor and Antimitochondrial Properties of Gossypol Enantiomers," Molecular Pharmacology, 37, 840-847 (1990). |
Benz et al., "Gossypol Enantiomers (+, -) Differentially Uncouple Tumor Mitochondria, Block Glutathione-S-Transferase Activity, and Inhibit Cellular Proliferation," 79th Annual Meeting of the American Association for Cancer Research, Proceedings, 29, 322 (1988). |
Benz et al., "Lactic Dehydrogenase Isozymers, 31P Magnetic Resonance Spectroscopy, and In Vitro Antimitochondrial Tumor Toxicity with Gossypol and Rhodamine-123," The Journal of Clinical Investigation, 79 (2), 517-523 (1987). |
Benz et al., "Selective Toxicity of Gossypol Against Epithelial Tumors and its Detection by Magnetic Resonance Spectroscopy," Contraception, 37 (3), 221-229 (1988). |
Bushunow et al., "Gossypol Treatment of recurrent Adult Malignant Gliomas," J. Neuro-Oncology, 43, 79-86 (1999). |
Cass et al., J. Agric. Food Chem., 52: 5822-5827 (2004). |
Cotton Cellulose Chemistr, "Gossypol prepn-from gossypol and anthranilate by alkaline hydrolysis of the anthranilate," SU 212245 (English abstract only) (1973). |
De Martino et al., "Electron microscopic and biochemical studies of the effect of Gossypol on Ehrlich ascites tumor cells," Caryologia, 35, 114-115 (1982). |
Dhaliwal et al., "Cytogenetic Analysis of a Gossypol-Induced Murine Myxosarcoma," Journal of the National Cancer Institute, 78 (6), 1203-1209 (1987). |
Flack et al., "Oral Gossypol in the Treatment of Metastatic Adrenal Cancer," J. Clin. Endocrinol. Metab.; 76(4), 1019-1024 (1993). |
Flack et al., "Treatment of adrenocortical carcinoma with gossypol," 81th Proceedings of the American Association for Cancer Research, 31, 198 (1990). |
Flordi et al., "The Effect of the Association of Gossypol and Lonidamine on the Energy Metabolism of Ehrlich Ascites Tumor Cells," Experimental and Molecular Pathology, 38, 322-335 (1983). |
Gura et al. Systems for Identifying new drugs are often faulty. Science, 1997, 278:1041-1042. * |
Han et al., "Gossypol in the Treatment of Endometriosis and Uterine Myoma," Contributions to Gynecology and Obstetrics, 16, 268-270 (1987). |
Haspel et al., "Cytocidal Effect of Gossypol on Cultured Murine Erythroleukemia Cells is Prevented by Serum Protein," The Journal of Pharmacology and Experimental Therapeutics, 229 (1), 218-225 (1984). |
Hei et al., ACTA Academiae Medicinae Sinicae, 61(9):527-529 (1981). |
Hu et al., "Gossypol Effects on Cultured Normal and Malignant Melanocytes," In Vitro Cellular & Developmental Biology, 22 (10), 583-588 (1986). |
Huang et al., "Resolution of Racemic Gossypol," Journal of Ethnopharmacology, 20, 13-20 (1987). |
Jaroszewski et al., "Action of Gossypol and Rhodamine 123 on Wild Type and Multidrug-resistant MCF-7 Human Breast Cancer Cells: 31P Nuclear Magnetic Resonance and Toxicity Studies," Cancer Research, 50, 6936-6943 (1990). |
Jaroszewski et al., Abstract, "Effects of Gossypol On Drug-Sensitive and Drug-Resistant Cancer Cells," Proc. Am. Assoc. Cancer Res 31, 377 (1990). |
Jingfang et al., "of Gossypol in Mice, Rats and Human Tumor Cell Lines and Its Possible Mechanism," Acta Academiae Medicinae Sinicae, 8 (6), 486-489 (1986). |
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431. * |
Jolad et al., "Tumor-Inhibitory Agent from Montezuma speciosissima (Malvaceae)," Journal of Pharmaceutical Sciences, 64 (11), 1889-1890 (1975). |
Joseph et al., "Cytotoxicity of enantiomers of gossypol," The British Journal of Cancer, 54 (3), 511-513 (1986). |
Kable et al., "Potency, Selectivity and Cell Cycle Dependence of Catechols in Human Tumor Cells In Vitro," Biochem. Pharmacol, 37, 1711-1715 (1988). |
Kai et al., "Resolution of Racemic Gossypol," Journal of the Chemical Society, (3), 168-169 (1985). |
Keniry et al., "Magnetic Resonance Spectroscopy (MRS) and Imaging (MRI) in the Evaluation of Tumor Growth and Chemotherapy Response," Proceedings, 77th Annual Meeting of the American Association for Cancer Research, 27, 384 (1986). |
Keniry et al., "The Effect of gossypol and 6-aminonicotinamide on tumor cell metabolism: A 31P-Magnetic Resonance spectroscopic study," Biochemical and Biophysical Research Communications, 164 (2), 947-953 (1989). |
Kim et al, Contraception 312 : 5966-72 (1984. * |
Kim et al., "Comparative In Vitro Spermicidal Effects of (±)-Gossypol, (+)-Gossypol, (-)-Gossypol, a Hyperthermic Sensitizer of HeLa Cells," Cancer Res., 45, 6338-6340 (1985). |
Kuznetsova et al., "Determination of the cytotoxic effect and antitumor activity of gossypol and some of its derivatives," Deposited Doc. (1979), Viniti 409-79, 7 pp. (Abstract Only). |
Kuznezova et al., "Measurement of Cytotoxic effects and anti-cancer properties of gossypol and its derivatives," Pharmacol. Toxicol., 1-7 (1979) (English abstract only). |
Ligueros et al., "Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells," British J. of Cancer, 76(1), 21-28 (1997). |
Matlin et al., "Large-Scale Resolution of Gossypol Enantiomers for Biological Evaluation," Contraception, 37 (3), 229-237 (1988). |
McClarty et al., "Ribonucleotide Reductase: An Intracellular Target for the Male Antifertility Agent, Gossypol," Biochem. Biophys. Res. Commun., 133, 300-305 (1985). |
McSheehy et al., "Gossypol, a cytoxic agent, may uncouple respiration of Ehrlich Ascites tumour cells," Biochemical Society Transactions, 16 (4), 616-617 (1988). |
Meiling, "Gossypol Treatment for Menopausal Functional Bleeding, Myoma of Uterus and Endometriosis-Preliminary Report," Acta Academiae Medicinae Sinicae, 2 (3), 168-170 (1980). |
Molla et al., Influence of 5-Hydroxytryptamine on the Combination Effect of Lonidamine or Gossypol and Hyperthermia on Ehrlich Tumour In Vivo, Anticancer Res., 7, 361-364 (1987). |
Moss et al., "Initiation and Proliferation of Gossypol-Producing Cotton Hairy Roots," 2005 Beltwide Cotton Conferences, New Orleans, Louisiana, p. 2092 (Jan. 4-7, 2005). |
Nayak et al., "Induction of Sister Chromatid Exchanges and Chromosome Damage by Gossypol in Bone Marrow Cells of Mice," Teratogenesis, Carcinogenesis, and Mutagenesis, 6 (2), 83-91 (1986). |
Ohuchi et al., "Inhibition by gossypol of tumor promoter-induced arachidonic acid metabolism in rat peritoneal macrophages," Biochimica et Biophysica Acta, 971, 85-91 (1988). |
Pirogov et al., "Postoperative Bronchopleural Complications in Combined Treatment of Pulmonary Cancer," Voprosy Onkologii, 20 (6), 24-28 (1974). |
Polsky et al., "Inactivation of Human Immunodeficiency Virus In Vitro by Gossypol," Contraception, 39(6), 579-587 (1989). |
Qian et al., "Gossypol: A Potential Antifertility Agent for Males," Annual Review of Pharmacological Toxicology, 24, 329-360 (1984). |
Rao et al. (1985) Cancer Chemother. Pharmacol. 15:2-25. * |
Rao et al., "Antitumor effects of gossypol on murine tumors," Cancer Chemotherapy. Pharmacology, 15, 20-25 (1985). |
Reidenberg, "Studies of Gossypol in the Treatment of Cancer," Reproductive Medicine: A Millennium Review, New York and London Pantheon, 305-308 (1999). |
Sampath et al., "A Rapid Procedure for the Resolution of Racemic Gossypol," Journal of the Chemical Society, (9), 649-650 (1986). |
Sausville et al. Cancer Research, 2006, vol. 66, pp. 3351-3354. * |
Senzer, "Hyperthermia: Chemotherapeutic and biologic response modifications," Strahlenther. Onkol., 165, 729-733 (1989). |
Stipanovic et al., "Occurrence of (+)- and (-)-Gossypol in Seed from Wild Species of Gossypium," 2005 Beltwide Cotton Conferences, New Orleans, Louisiana, p. 900 (Jan. 4-7, 2005). |
Stipanovic et al., J. Agric. Food Chem., 53(16): 6266-6271 (2005). |
Tanphaichitr et al., "Direct Effect of Gossypol on TR-ST Cells: Perturbation of Rhodamine 123 Accumulation in Mitochondria," Biology of Reproduction, 31, 1049-1060 (1984). |
The Merck Manual of Diagnosis and Therapy. 17th Edition, 1999, pp. 216-218. * |
Thoenes et al., "Cytotoxic Effects of Adriamycin, Bleomycin, Gossypol and Hydroxyanisol to Cultured Human Malignant Melanoma Cells," Journal of Cancer Research and Clinical Oncology, 113, S 46 (1987). |
Tso, "Gossypol Inhibits Ehrlich Ascites Tumor Cell Proliferation," Cancer Letters, 24, 257-261 (1984). |
Tuszynski et al., "Differential Cytotoxic Effect of Gossypol on Human Melanoma, Colon Carcinoma, and Other Tissue Culture Cell Lines," Cancer Research, 44, 768-771 (1984). |
Van Poznak et al., Breast Cancer Research and Treatment, 66, 239-248 (2001). |
Vermel et al., "Antitumor Activity of Gossypol in Experiments on Transplanted Tumours," Voprosy Oncoligii, 9 (12), 30-43 (1963). |
Vermel et al., Voprosy Onkologii 10, 88-97 (1964). |
Vermel, "The Search for Antitumour Substances of Plant Origin," Acta Unio Internationalis Contra Cancrum, 20, 211-213 (1964). |
Wang et al., "Effect of Gossypol on DNA Synthesis and Cell Cycle Progression of Mammalian Cells in Vitro," Cancer Research, 44, 35-38 (1984). |
Wu et al., "An in Vitro and in Vivo Study of Antitumor Effects of Gossypol on Human SW-13 Adrenocortical Carcinoma," Cancer Research, 49, 3754-3758 (1989). |
Wu et al., "In vitro antitumor activity of gossypol alone or in combination with amsacrine," European Journal of Pharmacology, 183 (2), 230 (1990). |
Wu et al., "Pharmacokinetics of (±)-, (+)-, and (-)-gossypol in humans and dogs," Clinical Pharmacology & Therapeutics, 39 (6), 613-618 (1986). |
Wu et al., Acta Academiae Medicinae Sinicae, 8(6):489 (Dec. 1986). |
Wu et al., J. Chromatography, 433, 141-148 (1988). |
Xu, J. of Science and Medicine of Jinan Univ., 2:40-42 (Jun. 1987). |
Xueqing et al., "Clinical Observation and Experimental Study of Gossypol in Treatment of Dysfunctional Menorrhagia, Endometriosis and Fibromyoma of Uterus," Chinese J. Interger. Trad. Western Med., 8, 197 & 216-217 (1988). |
Yerukhimov. "Treatment of Bladder Tumors with Gossipol and Ionol in Combination with Surgical Intervention," Voprosy Onkologii, 12 (2), 29-34 (1966). |
Yikang et al., "Studies on Resolution of Racemic Gossypol: Separation of Hexaacetates of S-1-Methylphenethylamino Derivative of (±) Gossypol," Scientia Sinica, 30 (3), 297-303 (1987). |
Yu, "Probing into the Mechanism of Action, Metabolism and Toxicity of Gossypol by Studying Its (+)- and (-)- Stereoisomers," Journal of Ethnopharmacology, 20, 65-78 (1987). |
Zhang et al., Acta Academiae Medicinae Sinicae, 7(5):385-387 (Oct. 1985). |
Zhang et al., Acta Academiae Medicinae Sinicae, 8(6):486-488 (Dec. 1986). |
Zheng et al., "Studies on the Resolution of Racemic Gossypol: IV. Use of Threo(-) or (+)-1-(p-Nitrophenyl)-1,3-Dihydroxypropylamine-2 as the Resolving Agent," Acta Pharmaceutica Sinica, 25 (6), 430-434 (1990). |
Zhou et al., Contraception, 37(3): 239-245 (1988). |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090105319A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
US9115061B2 (en) | 2007-10-19 | 2015-08-25 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
US20110112112A1 (en) * | 2009-10-08 | 2011-05-12 | Sanford-Burnham Medical Research Institute | Apogossypolone derivatives as anticancer agents |
US8937193B2 (en) | 2009-10-08 | 2015-01-20 | Sanford-Burnham Medical Research Institute | Apogossypolone derivatives as anticancer agents |
Also Published As
Publication number | Publication date |
---|---|
US5385936A (en) | 1995-01-31 |
US6114397A (en) | 2000-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE40862E1 (en) | Gossypolone for the treatment of cancer | |
US5225404A (en) | Methods of treating colon tumors with tumor-inhibiting camptothecin compounds | |
WO2019174571A1 (en) | Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance | |
US20050222258A1 (en) | Pharmaceuticals comprising shikonins as active constituent | |
SK282228B6 (en) | A pharmaceutical composition and its use | |
CN111346081B (en) | New use of pharmaceutical composition comprising n-pentanoic acid, indolpropanic acid and sodium n-butyrate | |
US6063814A (en) | Phorbol esters as anti-neoplastic and white blood cell elevating agents | |
WO2019228524A1 (en) | Pharmaceutical composition for treating kidney cancer and application thereof | |
US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
CN110585132A (en) | Quercetin nano micelle and preparation method and application thereof | |
WO2013071696A1 (en) | Use of five normal bases in humans for preparation of tumour drugs | |
KR950008767B1 (en) | Novel pharmacentical use of ebselen | |
WO2019214723A1 (en) | Application of chlorogenic acid and compositions thereof in preparation of drugs for treating squamous cell carcinoma | |
CN113925867A (en) | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs | |
CN110664807B (en) | Pharmaceutical composition with synergistic anti-melanoma efficacy and application thereof | |
CN101119721A (en) | Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis | |
JP2557303B2 (en) | Antitumor effect enhancer and antitumor agent | |
US4719213A (en) | Anti-cancer composition for delivering 5-fluorouracil | |
CN111481640B (en) | Anti-liver cancer microemulsion nano composition and application thereof | |
CN107007611A (en) | Application of the nomegestrol acetate in the medicine for preparing treatment carcinoma of endometrium | |
TW202038931A (en) | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor | |
CN111388665B (en) | Compound for treating tumor and preparation and application thereof | |
Ochiai et al. | Inhibition of experimental pulmonary metastasis in mice by β-cyclodextrin-benzaldehyde | |
KR100421261B1 (en) | Radiosensitizer containing phytosphingosine derivatives as the active ingredient | |
KAMURA et al. | Antitumor effect of thermodifferential chemotherapy with carboquone on Ehrlich carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |